Amgen Inc
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen EVENITY (romosozumab-aqqg by Year
EVENITY (romosozumab-aqqg — Postmenopausal Osteoporosis) — Worldwide reported sales growth YoY (%) (%)
Amgen EVENITY (romosozumab-aqqg: 34.0% in FY2025, down 1.0 pts from a year earlier.
Where the FY2025 figure comes from
“|| EVENITY ® | 1,600 | 500 | 2,100 | 1,563 | 34%”
Source: Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗
Reported in Form 8-K Product Sales Detail by Product and Geographic Region.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | EVENITY (romosozumab-aqqg — Postmenopausal Osteoporosis) — Worldwide reported sales growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 34.0% | -1.0 pts | Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 35.0% | -12.0 pts | Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗ |
| FY2023 | Dec 31, 2023 | 47.0% | -1.0 pts | Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗ |
| FY2022 | Dec 31, 2022 | 48.0% | -3.0 pts | Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗ |
| FY2021 | Dec 31, 2021 | 51.0% | -34.0 pts | Form 8-K (amgenq42021earningsrelease.htm, filed 2022-02-07) ↗ |
| FY2020 | Dec 31, 2020 | 85.0% | – | Form 8-K (amgn-20201231xq4ex991.htm, filed 2021-02-02) ↗ |
Cite this data
StockData. (2026). Amgen EVENITY (romosozumab-aqqg (%), annual FY2020–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-evenity-yoy
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.